This article is more than 5 years old. Information may no longer be current.

Spark Therapeutics posts $74.4 million quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spark Therapeutics reported a net loss of $74.4 million, or $2.40 per common share, in the second quarter of 2017 compared with a net loss of $28.7 million, or $1.04 per common share, in the second quarter of 2016.

Research and development costs increased from $19.6 million in 2016’s second quarter to $33 million this year, which was attributed to a $9.8 million increase in internal expenses and $3.6 million increase in external research and development mostly related to Luxturna (voretigene neparvovec), according to a company press release.

General and administrative expenses for the quarter increased from $10.7 million in 2016 to $26.7 million in 2017.

Revenue, associated with a collaboration with Pfizer, was $1.5 million in the second quarter compared with $1.3 million a year ago.